Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084555 | 0.82 | RAPGEF4 (0.35) | RAPGEF4ALDH1A1 | |
| SCHEMBL29196013 | 0.80 | RAPGEF4 (0.52) | RAPGEF4 | |
| SCHEMBL26244538 | 0.77 | CYP3A4 (0.40) | ALDH1A1 | |
| SCHEMBL13744812 | 0.77 | CYP3A4 (0.40) | RAPGEF4ALDH1A1 | |
| SCHEMBL18726361 | 0.77 | ALDH1A1 (0.38) | RAPGEF4ALDH1A1 | |
| SCHEMBL19121816 | 0.74 | LMNA (0.31) | RAPGEF4 | |
| SCHEMBL16105836 | 0.73 | SHBG (0.46) | RAPGEF4ALDH1A1 | |
| SCHEMBL24079376 | 0.72 | — | — | |
| SCHEMBL18183245 | 0.72 | CYP3A4 (0.41) | RAPGEF4 | |
| SCHEMBL1131928 | 0.72 | CYP3A4 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| CN-103958548-B | Use the manufacture method of the olefin block polymers of multiple transition-metal catalyst | SUMITOMO CHEMICAL CO.,LTD. (JP) | 2016-05-18 | — | — | CN | disclosed |
| CN-103958548-A | Method for producing olefin block polymer using plurality of types of transition metal catalysts | SUMITOMO CHEMICAL CO | 2014-07-30 | — | — | CN | disclosed |
| CN-101878236-B | Ethylene-alpha-olefin copolymer and molded body | SUMITOMO CHEMICAL CO | 2014-05-07 | — | — | CN | disclosed |
| CN-103732632-A | Method for producing olefin block polymer using group 4 transition metal complex | SUMITOMO CHEMICAL CO | 2014-04-16 | — | — | CN | disclosed |
| US-20120065351-A1 | ETHYLENE-ALPHA-OLEFIN COPOLYMER AND MOLDED ARTICLE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2009104785-A1 | CATALYST COMPONENT FOR POLYMERIZATION OF ETHYLENE AND PROCESS FOR PRODUCING ETHYLENE POLYMER (1) | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | RAPGEF4 557/4885ALDH1A1 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.